Recursion Pharmaceuticals (RXRX) Debt to Equity (2020 - 2025)
Recursion Pharmaceuticals' Debt to Equity history spans 6 years, with the latest figure at $0.02 for Q4 2025.
- For Q4 2025, Debt to Equity fell 37.81% year-over-year to $0.02; the TTM value through Dec 2025 reached $0.02, down 37.81%, while the annual FY2025 figure was $0.02, 37.81% down from the prior year.
- Debt to Equity reached $0.02 in Q4 2025 per RXRX's latest filing, down from $0.02 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.05 in Q3 2024 to a low of -$0.04 in Q1 2021.
- Average Debt to Equity over 5 years is $0.01, with a median of $0.0 recorded in 2023.
- Peak YoY movement for Debt to Equity: plummeted 90.87% in 2022, then surged 2055.72% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.0 in 2021, then fell by 5.37% to $0.0 in 2022, then surged by 123.34% to $0.0 in 2023, then skyrocketed by 976.39% to $0.03 in 2024, then tumbled by 37.81% to $0.02 in 2025.
- Per Business Quant, the three most recent readings for RXRX's Debt to Equity are $0.02 (Q4 2025), $0.02 (Q3 2025), and $0.02 (Q2 2025).